BIOMARKER:

EGFR L858R

A1 | Sensitive

A2 | Sensitive

B | Sensitive

C1 | Sensitive

C2 | Sensitive

C3 | Sensitive

C4 | Sensitive

D | Sensitive

A1 | Resistant

A2 | Resistant

B | Resistant

C1 | Resistant

C2 | Resistant

C3 | Resistant

C4 | Resistant

D | Resistant

Non Small Cell Lung Cancer

Lung Non-Squamous Non-Small Cell Cancer

Lung Adenocarcinoma

Lung Cancer

Lung Non-Small Cell Squamous Cancer

Germ Cell Tumors

Glioblastoma

Thyroid Gland Anaplastic Carcinoma

Colon Cancer

bevacizumab + erlotinib

EGFR L858R|Non Small Cell Lung Cancer|bevacizumab + erlotinib

EGFR L858R|Lung Adenocarcinoma|bevacizumab + erlotinib

EGFR L858R|Lung Cancer|bevacizumab + erlotinib

amivantamab-vmjw

EGFR L858R|Non Small Cell Lung Cancer|amivantamab-vmjw

EGFR L858R|Lung Non-Squamous Non-Small Cell Cancer|amivantamab-vmjw

icotinib

EGFR L858R|Non Small Cell Lung Cancer|icotinib

EGFR L858R|Lung Adenocarcinoma|icotinib

EGFR L858R|Lung Cancer|icotinib

EGFR L858R|Germ Cell Tumors|icotinib

gefitinib

EGFR L858R|Non Small Cell Lung Cancer|gefitinib

EGFR L858R|Lung Non-Squamous Non-Small Cell Cancer|gefitinib

EGFR L858R|Lung Adenocarcinoma|gefitinib

erlotinib

EGFR L858R|Non Small Cell Lung Cancer|erlotinib

EGFR L858R|Lung Adenocarcinoma|erlotinib

EGFR L858R|Lung Non-Small Cell Squamous Cancer|erlotinib

EGFR L858R|Thyroid Gland Anaplastic Carcinoma|erlotinib

gefitinib + rivoceranib

EGFR L858R|Non Small Cell Lung Cancer|gefitinib + rivoceranib

osimertinib

EGFR L858R|Non Small Cell Lung Cancer|osimertinib

EGFR L858R|Lung Non-Squamous Non-Small Cell Cancer|osimertinib

EGFR L858R|Lung Adenocarcinoma|osimertinib

EGFR L858R|Lung Cancer|osimertinib

gefitinib + ramucirumab

EGFR L858R|Non Small Cell Lung Cancer|gefitinib + ramucirumab

befotertinib

EGFR L858R|Non Small Cell Lung Cancer|befotertinib

afatinib

EGFR L858R|Non Small Cell Lung Cancer|afatinib

EGFR L858R|Lung Adenocarcinoma|afatinib

bevacizumab + atezolizumab

EGFR L858R|Non Small Cell Lung Cancer|bevacizumab + atezolizumab

EGFR L858R|Lung Non-Squamous Non-Small Cell Cancer|bevacizumab + atezolizumab

EGFR inhibitor

EGFR L858R|Non Small Cell Lung Cancer|EGFR inhibitor

EGFR L858R|Lung Adenocarcinoma|EGFR inhibitor

EGFR L858R|Lung Non-Small Cell Squamous Cancer|EGFR inhibitor

aumolertinib

EGFR L858R|Non Small Cell Lung Cancer|aumolertinib

EGFR L858R|Lung Adenocarcinoma|aumolertinib

anlotinib + icotinib

EGFR L858R|Non Small Cell Lung Cancer|anlotinib + icotinib

EGFR L858R|Lung Non-Squamous Non-Small Cell Cancer|anlotinib + icotinib

tislelizumab

EGFR L858R|Non Small Cell Lung Cancer|tislelizumab

EGFR L858R|Lung Non-Squamous Non-Small Cell Cancer|tislelizumab

PD-L1 inhibitor

EGFR L858R|Non Small Cell Lung Cancer|PD-L1 inhibitor

Tyrosine kinase inhibitor

EGFR L858R|Non Small Cell Lung Cancer|Tyrosine kinase inhibitor

Immunotherapy

EGFR L858R|Non Small Cell Lung Cancer|Immunotherapy

Angiogenesis inhibitor

EGFR L858R|Non Small Cell Lung Cancer|Angiogenesis inhibitor

PD1 inhibitor

EGFR L858R|Non Small Cell Lung Cancer|PD1 inhibitor

bevacizumab

EGFR L858R|Non Small Cell Lung Cancer|bevacizumab

osimertinib + afatinib

EGFR L858R|Non Small Cell Lung Cancer|osimertinib + afatinib

bevacizumab + aumolertinib

EGFR L858R|Non Small Cell Lung Cancer|bevacizumab + aumolertinib

dacomitinib

EGFR L858R|Non Small Cell Lung Cancer|dacomitinib

pembrolizumab

EGFR L858R|Lung Adenocarcinoma|pembrolizumab

bevacizumab + dacomitinib

EGFR L858R|Lung Adenocarcinoma|bevacizumab + dacomitinib

anlotinib + temozolomide + aumolertinib

EGFR L858R|Glioblastoma|anlotinib + temozolomide + aumolertinib

furmonertinib

EGFR L858R|Non Small Cell Lung Cancer|furmonertinib

osimertinib + ABT 263

EGFR L858R|Non Small Cell Lung Cancer|osimertinib + ABT 263

osimertinib + gefitinib

EGFR L858R|Non Small Cell Lung Cancer|osimertinib + gefitinib

EGF816

EGFR L858R|Non Small Cell Lung Cancer|EGF816

osimertinib + savolitinib

EGFR L858R|Non Small Cell Lung Cancer|osimertinib + savolitinib

cisplatin + erlotinib + docetaxel

EGFR L858R|Non Small Cell Lung Cancer|cisplatin + erlotinib + docetaxel

rociletinib

EGFR L858R|Non Small Cell Lung Cancer|rociletinib

bevacizumab + icotinib

EGFR L858R|Non Small Cell Lung Cancer|bevacizumab + icotinib

U3-1402

EGFR L858R|Non Small Cell Lung Cancer|U3-1402

lazertinib

EGFR L858R|Non Small Cell Lung Cancer|lazertinib

bevacizumab + osimertinib

EGFR L858R|Non Small Cell Lung Cancer|bevacizumab + osimertinib

icotinib + furmonertinib

EGFR L858R|Non Small Cell Lung Cancer|icotinib + furmonertinib

amivantamab-vmjw + lazertinib

EGFR L858R|Non Small Cell Lung Cancer|amivantamab-vmjw + lazertinib

camrelizumab + rivoceranib

EGFR L858R|Non Small Cell Lung Cancer|camrelizumab + rivoceranib

afatinib + DFP-14323

EGFR L858R|Non Small Cell Lung Cancer|afatinib + DFP-14323

osimertinib + MEDI9447

EGFR L858R|Non Small Cell Lung Cancer|osimertinib + MEDI9447

olaparib + gefitinib

EGFR L858R|Non Small Cell Lung Cancer|olaparib + gefitinib

erlotinib + anlotinib

EGFR L858R|Non Small Cell Lung Cancer|erlotinib + anlotinib

anlotinib + APL-502

EGFR L858R|Non Small Cell Lung Cancer|anlotinib + APL-502

gefitinib + anlotinib

EGFR L858R|Non Small Cell Lung Cancer|gefitinib + anlotinib

icotinib + aumolertinib

EGFR L858R|Non Small Cell Lung Cancer|icotinib + aumolertinib

KN046

EGFR L858R|Non Small Cell Lung Cancer|KN046

AZD3759

EGFR L858R|Non Small Cell Lung Cancer|AZD3759

bevacizumab + gefitinib

EGFR L858R|Non Small Cell Lung Cancer|bevacizumab + gefitinib

erlotinib + ramucirumab

EGFR L858R|Non Small Cell Lung Cancer|erlotinib + ramucirumab

crizotinib + osimertinib

EGFR L858R|Lung Cancer|crizotinib + osimertinib

neratinib + PF-05212384

EGFR L858R|Non Small Cell Lung Cancer|neratinib + PF-05212384

VRN11

EGFR L858R|Non Small Cell Lung Cancer|VRN11

neratinib

EGFR L858R|Non Small Cell Lung Cancer|neratinib

BMS-722782

EGFR L858R|Lung Cancer|BMS-722782

H002

EGFR L858R|Non Small Cell Lung Cancer|H002

panitumumab

EGFR L858R|Colon Cancer|panitumumab

BI-4020

EGFR L858R|Non Small Cell Lung Cancer|BI-4020

cetuximab

EGFR L858R|Colon Cancer|cetuximab

durvalumab

EGFR L858R|Non Small Cell Lung Cancer|durvalumab

erlotinib + ado-trastuzumab emtansine

EGFR L858R|Non Small Cell Lung Cancer|erlotinib + ado-trastuzumab emtansine

durvalumab + gefitinib

EGFR L858R|Non Small Cell Lung Cancer|durvalumab + gefitinib

BLU-945 + BLU-701

EGFR L858R|Non Small Cell Lung Cancer|BLU-945 + BLU-701

osimertinib + BLU-701

EGFR L858R|Non Small Cell Lung Cancer|osimertinib + BLU-701

CH7233163

EGFR L858R|Non Small Cell Lung Cancer|CH7233163

osimertinib + BLU-945

EGFR L858R|Non Small Cell Lung Cancer|osimertinib + BLU-945